The successful financing and clear clinical timeline for vidofludimus calcium reduce near-term dilution risk and provide visibility into potential value inflection points in 2026-2027. Traders should monitor for top-line data from the ENSURE trials by year-end 2026 as a key catalyst.
Price Chart
Executive Summary
Immunic, Inc. reported its 2025 financial results, showing a reduced net loss of $97.2 million compared to $100.5 million in 2024, and announced a $200 million private placement with potential for an additional $200 million. The funds will support the completion of Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis, with top-line data expected by year-end 2026, and preparations for a potential NDA submission in mid-2027.
Key Financial Metrics
Key Facts
- Net loss decreased to $97.2 million in 2025 from $100.5 million in 2024
- Raised $200 million in a private placement, with potential for up to $200 million more
- Proceeds expected to fund operations into late 2027, covering ENSURE top-line data and NDA submission
- Top-line data from Phase 3 ENSURE trials in relapsing multiple sclerosis expected by end of 2026
- Plans to initiate a Phase 3 program in primary progressive multiple sclerosis later in 2026
Financial Impact
Raised $200 million in gross proceeds with potential for up to $400 million total, extending cash runway into late 2027
Risk Factors
- Clinical trial results may not meet expectations
- Additional capital may be required beyond the current funding runway
- Regulatory approval is not guaranteed even with positive trial data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193805-26-000181 |
| Document: e665186_8k-immunic.htm | 0001193805-26-000181 |
| Document: 0001193805-26-000181-index-headers.html | 0001193805-26-000181 |
| Document: 0001193805-26-000181-index.html | 0001193805-26-000181 |
| Document: 0001193805-26-000181.txt | 0001193805-26-000181 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $12.19 | awaiting T+60 | — | $7.51 (−38.35%) |
Aug 11, 2026 11w ago | 8-K | $15.48 | awaiting T+60 | — | $7.51 (−51.45%) |
Jul 14, 2026 15w ago | 8-K | $14.69 $7.63 | ▼ −48.06% | ▼ −51.44% | $7.51 (−48.84%) |
Jun 29, 2026 17w ago | 8-K | $15.37 $9.37 | ▼ −39.04% | ▼ −42.60% | $7.51 (−51.11%) |
May 19, 2026 22w ago | 3 | $11.55 $16.06 | ▲ +39.05% | ▲ +34.04% | $7.51 (−34.94%) |
May 19, 2026 23w ago | 8-K | $11.60 $16.58 | ▲ +42.93% | ▲ +36.64% | $7.51 (−35.22%) |
Apr 30, 2026 25w ago | S-3/A | $9.65 $13.34 | ▼ −38.24% | ▼ −35.17% | $7.51 (+22.12%) |
Apr 23, 2026 26w ago | 8-K | $9.18 $15.00 | ▲ +63.40% | ▲ +58.38% | $7.51 (−18.14%) |
Apr 14, 2026 27w ago | 8-K | $11.10 $14.77 | ▲ +33.06% | ▲ +24.93% | $7.51 (−32.30%) |
Apr 10, 2026 28w ago | 8-K | $12.20 $14.77 | ▲ +21.07% | ▲ +12.14% | $7.51 (−38.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers